Therapeutics News and Research

RSS

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Cornerstone's CPI-613 drug candidate chosen as 2014 Top 10 Most Interesting Oncology Projects to Watch

Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.

14 Nov 2014

New scientific paper reveals gaps in knowledge about preterm birth

Preterm birth is now the leading cause of death for children under 5 worldwide, and a new scientific paper reveals a startling lack of knowledge about what causes it and how to prevent it.

13 Nov 2014

BioCision announces ThawSTAR™ automated sample thawing system

BioCision, LLC, a leader in advanced products to improve biospecimen handling and standardization, today announced the availability of ThawSTAR™ automated sample thawing system, a breakthrough technology that addresses the “last mile” in the cryopreservation process. Utilizing the patent-pending STAR™ adaptive sensing technology for rapid and standardized thawing and recovery of cells and other biospecimens, ThawSTAR system tailors the thaw cycle to the specific characteristics of each frozen sample.

12 Nov 2014

Effecting changes to FosB gene could help control addiction, depression

Regulation of a single, specific gene in a brain region related to drug addiction and depression is sufficient to reduce drug and stress responses, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published October 27 online in the journal Nature Neuroscience.

12 Nov 2014

Enterome, AbbVie to develop novel diagnostic products, therapies for microbiome-related diseases

ENTEROME Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a thorough understanding of the gut microbiome, announces that it has entered into a collaborative development agreement with AbbVie.

12 Nov 2014

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2.

12 Nov 2014

New findings could help develop therapeutic options for glycogen storage disease

Glycogen storage disorders, which affect the body's ability to process sugar and store energy, are rare metabolic conditions that frequently manifest in the first years of life. Often accompanied by liver and muscle disease, this inability to process and store glucose can have many different causes, and can be difficult to diagnose.

11 Nov 2014

HLD-200 successfully meets primary endpoint in Phase III study

Highland Therapeutics Inc., a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has reported positive top-line results from its recently completed Phase III study.

11 Nov 2014

BioInfect 2014 conference explores global anti-microbial agenda

This year’s unique BioInfect conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry,was a major success.

10 Nov 2014

UF Health researcher finds way to grow human norovirus

Noroviruses are pernicious intestinal viruses. They cause violent vomiting and diarrhea, and people ill with the virus remain contagious up to three days after they seem to recover.

9 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.

7 Nov 2014

Even brief workouts can reduce risk of relapse during meth withdrawal

Scientists at The Scripps Research Institute (TSRI) have found that even brief workouts can reduce the risk of relapse in rats withdrawing from methamphetamine. In addition, the team found that exercise affected the neurons in a brain region that had never before been associated with meth withdrawal, suggesting a new direction for drug development.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.

5 Nov 2014

Scientists uncover small set of genes critical in aging and neurodegenerative disease

Aging is the most significant and universal risk factor for developing neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's, Parkinson's and Huntington's diseases. This risk increases disproportionately with age, but no one really knows why.

4 Nov 2014

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Broad Institute, UC Berkeley and UCSC receive NCI Cancer Genomics Cloud Pilot contract

A team from the Broad Institute, the University of California, Berkeley, and the University of California, Santa Cruz, was awarded one of three National Cancer Institute Cancer Genomics Cloud Pilot contracts with the goal of building a system that will enable large-scale analysis of The Cancer Genome Atlas and other datasets by co-locating the data and the required computing resources in one cloud environment.

31 Oct 2014

Scientists develop new system to treat a host of genetic conditions

As potential next-generation therapeutics and research tools, few life sciences technologies hold more promise than genome-editing proteins – molecules that can be programmed to alter specific genes in order to treat or even cure genetic diseases.

31 Oct 2014

Therapeutics News and Research

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Cornerstone's CPI-613 drug candidate chosen as 2014 Top 10 Most Interesting Oncology Projects to Watch

New scientific paper reveals gaps in knowledge about preterm birth

BioCision announces ThawSTAR™ automated sample thawing system

Effecting changes to FosB gene could help control addiction, depression

Enterome, AbbVie to develop novel diagnostic products, therapies for microbiome-related diseases

Study reports anti-cancer activity in mice treated with experimental drug TAK-733

New findings could help develop therapeutic options for glycogen storage disease

HLD-200 successfully meets primary endpoint in Phase III study

BioInfect 2014 conference explores global anti-microbial agenda

UF Health researcher finds way to grow human norovirus

Johnson & Johnson completes acquisition of Alios BioPharma

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Even brief workouts can reduce risk of relapse during meth withdrawal

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Scientists uncover small set of genes critical in aging and neurodegenerative disease

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Broad Institute, UC Berkeley and UCSC receive NCI Cancer Genomics Cloud Pilot contract

Scientists develop new system to treat a host of genetic conditions

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News